huTCF4-R580W Mouse
Product Name
huTCF4-R580W Mouse
Product ID
C002101
Strain Name
C57BL/6JCya-Tcf4em1(hTCF4*R580W)/Cya
Backgroud
C57BL/6JCya
Status
When using this mouse strain in a publication, please cite “huTCF4-R580W Mouse (Catalog C002101) were purchased from Cyagen.”
Product Type
Age
Genotype
Sex
Quantity
Gene Name
TCF4
Gene Alias
E2-2, FCD2, ITF2, PTHS, SEF2, CDG2T, FECD3, ITF-2, SEF-2, TCF-4, SEF2-1, SEF2-1A, SEF2-1B, SEF2-1D, bHLHb19
NCBI ID
Chromosome
Chr 18 (Human)
MGI ID
Datasheet
Strain Description
Pitt-Hopkins syndrome (PTHS) is a rare autosomal dominant neurodevelopmental disorder. It is primarily caused by abnormal development of the nervous system. Patients may present with severe intellectual disability, global developmental delay, characteristic facial features, respiratory abnormalities, epilepsy, severe constipation and gastroesophageal reflux as manifestations of autonomic dysfunction, as well as language absence or severe limitation, motor developmental delay, and behavioral abnormalities [1]. The pathogenesis of PTHS is mainly associated with haploinsufficiency of the transcription factor 4 (TCF4) gene. The TCF4 gene is located on chromosome 18q21.2 and encodes a type I basic helix‑loop‑helix transcription factor that plays a critical role in nervous system development and function maintenance, participating in neuronal differentiation and migration, regulation of neuronal excitability, and neuroplasticity [2-3]. Loss of TCF4 function leads to aberrant expression of its downstream target genes, thereby affecting normal cerebral cortical development and ultimately causing PTHS. The c.1738C>T (p.R580W) mutation, which substitutes arginine with tryptophan at position 580 of the TCF4 protein, abolishes the in vitro DNA‑binding ability of TCF4 homodimers and is one of the pathogenic missense mutations causing PTHS [4]. Unlike the common founder mutations in familial dysautonomia, TCF4 p.R580W usually occurs as a de novo heterozygous mutation, not detected in the parents, and carries a low familial recurrence risk [2]. The overall prevalence of PTHS is estimated at approximately one in several tens to hundreds of thousands of newborns. Currently, there is no precise targeted therapy; treatment mainly consists of multidisciplinary management [2,5].
The huTCF4-R580W mouse is a humanized mutant model generated by gene editing technology, in which the p.R580W (CGG→TGG) point mutation is introduced into exon 18 of the human TCF4 gene in the huTCF4 mouse (Catalog No.: C002071). This model serves as a key preclinical model for Pitt‑Hopkins syndrome (PTHS) and can be used for studying PTHS disease mechanisms, drug screening, and preclinical pharmacological efficacy evaluation.
Reference
de Winter CF, Baas M, Bijlsma EK, van Heukelingen J, Routledge S, Hennekam RC. Phenotype and natural history in 101 individuals with Pitt-Hopkins syndrome through an internet questionnaire system. Orphanet J Rare Dis. 2016;11:37.
Sepp M, Pruunsild P, Timmusk T. Pitt-Hopkins syndrome-associated mutations in TCF4 lead to variable impairment of the transcription factor function ranging from hypomorphic to dominant-negative effects. Hum Mol Genet. 2012;21(13):2873-2888.
Brockschmidt A, Todt U, Ryu S, et al. Severe mental retardation with breathing abnormalities (Pitt-Hopkins syndrome) is caused by haploinsufficiency of the neuronal bHLH transcription factor TCF4. Hum Mol Genet. 2007;16(12):1488-1494.
Amiel J, Rio M, de Pontual L, et al. Mutations in TCF4, encoding a class I basic helix-loop-helix transcription factor, are responsible for Pitt-Hopkins syndrome, a severe epileptic encephalopathy associated with autonomic dysfunction. Am J Hum Genet. 2007;80(5):988-993.
Orphanet: Pitt-Hopkins syndrome, ORPHA:2896
Strain Strategy
The p.R580W (CGG→TGG) point mutation was introduced into exon 18 of the human TCF4 gene.
Figure 1. Gene editing strategy for the huTCF4-R580W mouse model.
Application Area
Research on Pitt-Hopkins syndrome (PTHS);
Research on the disease mechanism of PTHS;
Drug screening for PTHS and preclinical evaluation of pharmacology and efficacy.
Contact Us
Connect with our experts for your custom animal model needs. Please fill out the form below to start a conversation or request a quote.
Cyagen values your privacy. We’d like to keep you informed about our latest offerings and insights. Your preferences:
You may unsubscribe from these communications at any time. See our Privacy Policy for details on opting out and data protection.
By clicking the button below, you consent to allow Cyagen to store and process the personal information submitted in this form to provide you the content requested.
